Sam Illingworth

Sam Illingworth has extensive work experience in the pharmaceutical and biotechnology industry. They began their career as a Scientist at PsiOxus Therapeutics Ltd in February 2007 and held this role until December 2017. From January 2018 to May 2020, they worked as a Senior Scientist at the same company. Sam then joined GammaDelta Therapeutics in May 2020 as a Principal Scientist and remained there until March 2022. In April 2022, they became a Principal Scientist at Takeda Oncology, where they worked until April 2023. Currently, Sam is the Head of Translation Research at Purespring Therapeutics, starting in April 2023.

Sam Illingworth completed their BSc in Chemistry from the University of Warwick, where they studied from 2002 to 2005. Later, they pursued a Masters degree in Immunology and Immunogenetics at The University of Manchester between 2011 and 2013.